Clinical Oncology Next Generation Sequencing Market Hit US$ 3.4 Billion By 2034

Overview

New York, NY – June 04, 2025 – Global Clinical Oncology Next Generation Sequencing Market size is expected to be worth around US$ 3.4 billion by 2034 from US$ 0.7 billion in 2024, growing at a CAGR of 17.2% during the forecast period 2025 to 2034.

A leading research institution today announced the launch of a next-generation sequencing (NGS) platform for clinical oncology. The platform facilitates comprehensive genomic profiling of tumors, enabling personalized treatments. Through high-throughput sequencing, detailed insights into genetic mutations, copy number variations, and structural alterations can now be obtained more rapidly than before.

Clinical workflows have been enhanced by a streamlined sample preparation process, reducing turnaround times and ensuring high data accuracy. The bioinformatics pipeline has been optimized to deliver actionable reports, highlighting biomarkers that have been clinically validated by regulatory authorities. Oncologists will be equipped with robust data to guide precision medicine approaches, including targeted therapies and immunotherapy selection.

A spokesperson stated, “The adoption of this NGS platform is expected to transform care pathways and improve patient outcomes. Enhanced sensitivity and specificity have been achieved through advanced sequencing chemistries.” The platform has received regulatory clearance for use in accredited laboratories and will be available to hospitals and diagnostic centers by the third quarter.

Industry analysts project that the global NGS market in clinical oncology will experience significant growth, driven by increasing demand for personalized treatments. Training programs will be provided for laboratory personnel to ensure seamless implementation. Support services, including technical assistance and data management solutions, will also be offered.

Key Takeaways

• In 2023, the global Clinical Oncology Next Generation Sequencing (NGS) market generated revenue of US$ 7 billion and is projected to reach approximately US$ 3.4 billion by 2033, registering a compound annual growth rate (CAGR) of 17.2% over the forecast period.
• By workflow type, the market is segmented into NGS sequencing, NGS pre-sequencing, and NGS data analysis. Among these, NGS sequencing accounted for the largest market share of 45.8% in 2023, driven by increasing clinical adoption for precision oncology applications.
• In terms of technology, the market is categorized into whole genome sequencing, targeted sequencing & resequencing, and whole exome sequencing. Targeted sequencing & resequencing emerged as the leading segment, holding a 48.6% share, attributed to its cost-efficiency and clinical relevance in identifying actionable mutations.
• By application, the market is classified into screening, companion diagnostics, and others. The screening segment dominated with a 52.3% revenue share, reflecting growing emphasis on early cancer detection and genetic risk assessment.
• Regarding end-use, the market is bifurcated into hospitals & clinics and laboratories. The laboratories segment led the market, capturing 57.4% of the revenue, due to the rising outsourcing of genomic testing services.
• North America remained the dominant regional market in 2023, accounting for a 41.3% share, supported by advanced healthcare infrastructure and increasing clinical integration of NGS technologies.

Segmentation Analysis

• Workflow Type Analysis: In 2023, the NGS sequencing segment led the market with a 45.8% share, driven by its critical role in cancer research and diagnosis. It enables high-throughput and detailed genomic profiling, essential for identifying cancer-related mutations. As demand grows for personalized oncology solutions, the precision and depth of data offered by NGS sequencing support its expanded adoption, especially in treatment planning and clinical decision-making for various cancer types.
• Technology Analysis: Targeted sequencing and resequencing dominated the technology segment in 2023, securing a 48.6% market share. This method focuses on specific genomic regions, making it a cost-effective and efficient tool for detecting cancer-related mutations. As the oncology field embraces tailored therapies, targeted sequencing technologies are becoming vital for identifying actionable genetic markers. The rising use of precision treatments based on mutation profiles is expected to accelerate the demand for this technology in cancer care.
• Application Analysis: The screening segment accounted for 52.3% of market revenue in 2023, reflecting a strong focus on early cancer detection. NGS-based screening enables the identification of key genetic mutations and biomarkers at early disease stages, improving treatment outcomes. Technological advances, particularly in liquid biopsy and non-invasive diagnostics, are boosting adoption. The growing emphasis on personalized therapies linked to genetic profiles is expected to sustain the momentum of screening as a dominant application area in clinical oncology NGS.
• End-Use Analysis: Laboratories led the end-use segment with 57.4% of the revenue in 2023, driven by increasing implementation of genomic testing in cancer research and diagnostics. Both hospital-based and independent labs are integrating NGS technologies to support more precise cancer diagnosis and treatment planning. As personalized oncology continues to evolve, the demand for accurate, high-throughput genomic data is pushing laboratories to adopt advanced NGS platforms, reinforcing their central role in the precision medicine landscape.

Market Segments

Workflow Type

• NGS Sequencing
• NGS Pre-Sequencing
• NGS Data Analysis

Technology

• Whole Genome Sequencing
• Targeted Sequencing & Resequencing
• Whole Exome Sequencing

Application

• Screening
  • Sporadic Cancer
  • Inherited Cancer
• Companion Diagnostics
• Others

End-use

• Hospitals & Clinics
• Laboratories

Regional Analysis

In 2023, North America led the Clinical Oncology Next Generation Sequencing (NGS) market, capturing a 41.3% revenue share. The high regional cancer burden, with over 600,000 annual deaths in the U.S. and 80,000 in Canada (WebMD, 2022), has driven demand for advanced diagnostic tools. The integration of NGS in clinical oncology has enabled precise detection of genetic mutations, supporting the adoption of personalized treatment strategies. Favorable regulatory frameworks, robust healthcare infrastructure, and extensive funding for genomic research have further accelerated NGS deployment. Additionally, AI-driven genomic data analysis has improved the efficiency and accuracy of sequencing, increasing adoption rates across the region.

Meanwhile, Asia Pacific is anticipated to register the fastest CAGR during the forecast period due to rising cancer incidence and expanding diagnostic capabilities. Countries such as China, India, and Japan are investing heavily in healthcare infrastructure and precision medicine initiatives. Collaborative efforts between global NGS firms and local institutions are enhancing accessibility to cutting-edge genomic technologies. Increasing healthcare expenditure, growing awareness about early cancer detection, and the rise of medical tourism are expected to support the rapid growth of NGS adoption in the region.

Emerging Trends

• The adoption of next-generation sequencing (NGS) by practicing oncologists has become widespread. A nationally representative survey in 2017 found that most U.S. cancer specialists were using NGS tests to guide treatment decisions for their patients. This reflects a broader shift toward precision medicine, wherein genomic profiling informs the selection of targeted therapies.
• Noninvasive liquid biopsies—testing circulating tumor DNA (ctDNA) from blood samples are gaining traction. NGS-based liquid biopsy methods can detect tumor-derived mutations months before conventional imaging reveals progression, offering a way to monitor disease and adjust treatment earlier. As these assays become more sensitive and cost-effective, their use is expanding beyond research into routine clinical care.
• Minimal residual disease (MRD) assessment using NGS is emerging as a key tool. Tumor-informed MRD assays rely on sequencing a patient’s tumor to identify unique mutations and then tracking those specific mutations in plasma; this approach can detect residual disease at levels often a 10-fold difference (1 log) compared to traditional methods. Tumor-agnostic MRD tests using fixed NGS panels without prior tumor sequencing—are also under evaluation for faster turnaround when tumor tissue is unavailable.
• Integration of immunotherapy-related biomarkers via NGS is accelerating. For example, NCI-MATCH Arm Z1D recently demonstrated that NGS-based microsatellite instability (MSI) scoring can predict which patients with mismatch repair-deficient tumors benefit from nivolumab (an anti-PD-1 therapy). This trend underscores the role of NGS in identifying patients eligible for checkpoint inhibitors.
• Germline and somatic multigene panels have become more affordable, driving broader genetic risk assessment in oncology. In prostate cancer, several clinical laboratories now offer NGS-based hereditary cancer panels at costs comparable to single-gene testing. As patent barriers have fallen, these panels enable simultaneous screening of dozens of genes implicated in cancer predisposition.

Use Cases

• Targeted Therapy Selection in Solid Tumors: In non-small cell lung cancer (NSCLC), comprehensive NGS panels are part of the standard workup to identify actionable mutations (e.g., EGFR, ALK, ROS1). At a large academic center in Los Angeles, molecular testing patterns showed that NGS detected mutations in over 30% of NSCLC cases that were missed by single-gene PCR assays. By revealing less common driver alterations, NGS enables oncologists to enroll patients in matched targeted therapy trials, improving response rates.
• Minimal Residual Disease Monitoring in Hematologic Malignancies: In pediatric leukemia, NGS quantitation of leukemia-specific immunoglobulin (IG) or T-cell receptor (TCR) rearrangements can detect MRD at levels 10 times lower than flow cytometry. PDQ guidance notes that comparing NGS-based MRD levels often shows a one-log difference, which is critical for stratifying relapse risk and tailoring post-remission therapy. Early MRD detection allows for timely intervention, reducing relapse rates in high-risk patients.
• Liquid Biopsy for Treatment Response and Resistance: Clinicians increasingly use NGS-based liquid biopsies to monitor ctDNA dynamics during therapy. Studies cited by the National Cancer Institute show that ctDNA levels drop by over 90% in responding colorectal cancer patients within two treatment cycles, often before radiographic changes appear. Conversely, rising ctDNA levels can signal emerging resistance mutations (e.g., KRAS in colorectal cancer), prompting switches to alternative regimens earlier than imaging alone would allow.
• Germline Risk Assessment and Counseling: Multigene NGS panels for inherited cancer predisposition have become standard in prostate, breast, and ovarian cancer clinics. The PDQ summary for prostate genetics indicates that, since 2020, multiple labs offer panels covering 20–80 genes (e.g., BRCA1/2, ATM, CHEK2) at prices similar to single-gene tests. Identifying a pathogenic variant in 5–10% of tested prostate cancer patients can guide prophylactic measures, inform family counseling, and influence treatment (e.g., PARP inhibitors for BRCA-mutated cases).
• Immunotherapy Biomarker Discovery: NGS-based MSI scoring has been validated as a predictive biomarker for immunotherapy. A 2025 study from the NCI-MATCH trial showed that patients with mismatch repair-deficient tumors who had high MSI scores by NGS experienced a 60% objective response rate to nivolumab, compared to 10% in MSS (microsatellite-stable) cases. By integrating MSI scoring into routine NGS panels, clinicians can select immunotherapy-eligible patients more accurately, enhancing outcomes in mismatch repair-deficient cancers.

Conclusion

The Clinical Oncology Next Generation Sequencing (NGS) market is undergoing rapid transformation, driven by technological advancements, increasing cancer prevalence, and the global shift toward precision medicine. With robust growth expected through 2034, NGS is enabling earlier detection, personalized therapy selection, and improved monitoring of treatment outcomes.

Innovations such as liquid biopsy, MRD assessment, and immunotherapy biomarker integration are expanding clinical utility. As accessibility improves and costs decline, adoption across hospitals, laboratories, and research institutions is expected to rise significantly. Supported by strong regional initiatives, particularly in North America and Asia Pacific, NGS is poised to redefine cancer diagnostics and patient care globally.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF